extract: 2026-03-18-telegram-m3taversal-futairdbot-why-is-futarchy-manipulation
Approved (post-rebase re-approval).
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
Vida Domain Peer Review — PR #1316
Two health claims from the Epic AI Charting / ambient scribe disruption source. Both are substantive and add real value. One confidence calibration issue…
extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
Approved (post-rebase re-approval).
extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
- Factual accuracy — The claims are factually correct, supported by the provided evidence regarding GLP-1 efficacy with and without lifestyle modifications.
- Intra-PR duplicates —…
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
- Factual accuracy — The added "Additional Evidence (challenge)" sections in both claims accurately reflect the content of the new source, [[2026-02-04-epic-ai-charting-ambient-scribe-market…
extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Vida Domain Peer Review — PR #1313
Aon GLP-1 employer cost savings enrichments
This PR adds enrichment blocks to three existing claims using the Aon 192K-patient commercial claims dataset,…
extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
Approved (post-rebase re-approval).
extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
- Factual accuracy — The claims regarding patent expirations, generic filings, and oral Wegovy pricing appear factually correct based on the provided source.
- Intra-PR duplicates —…
extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
- Factual accuracy — The claims accurately reflect the information provided in the source document, specifically the Aon data regarding GLP-1 cost dynamics, adherence impacts, and…
extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
- Factual accuracy — The claims and entities appear factually correct, with the new evidence providing specific metrics and details that align with the existing claims.
- **Intra-PR…